Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucagon and diabetes.

P Raskin, R H Unger

    The Medical Clinics of North America
    |July 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Glucagon plays a key role in diabetes pathogenesis. Suppressing glucagon, along with insulin, can correct hyperglycemia and hyperglucagonemia in diabetic patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.

    Diabetic medicine : a journal of the British Diabetic Association·2018
    Same author

    Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).

    Diabetes, obesity & metabolism·2016
    Same author

    AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

    Diabetes, obesity & metabolism·2015
    Same author

    Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.

    Diabetes, obesity & metabolism·2011
    Same author

    Glycaemic control with liraglutide: the phase 3 trial programme.

    International journal of clinical practice. Supplement·2010
    Same author

    Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.

    Diabetes, obesity & metabolism·2009
    Same journal

    Care Transitions Continue to Evolve.

    The Medical clinics of North America·2026
    Same journal

    Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

    The Medical clinics of North America·2026
    Same journal

    Care Transitions and Value-Based Payment Models in the United States.

    The Medical clinics of North America·2026
    Same journal

    Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

    The Medical clinics of North America·2026
    Same journal

    Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

    The Medical clinics of North America·2026
    Same journal

    Social Determinants of Health: Unique Considerations in Transitions of Care.

    The Medical clinics of North America·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Diabetes Research

    Background:

    • Glucagon is essential in the pathogenesis of syndromes resulting from complete insulin deficiency.
    • Elevated glucagon levels contribute to hyperglycemia in diabetic individuals with fixed insulin levels.

    Purpose of the Study:

    • To evaluate the role of glucagon in diabetes.
    • To investigate the efficacy of suppressing glucagon in diabetes management.

    Main Methods:

    • Review of evidence regarding glucagon's role in diabetes.
    • Analysis of treatment outcomes with insulin therapy supplemented by somatostatin.

    Main Results:

    • Glucagon is crucial for the full syndrome of complete insulin deficiency.

    Related Experiment Videos

  • In diabetics with stable insulin, increased glucagon causes hyperglycemia.
  • Somatostatin, by suppressing glucagon and growth hormone, corrects hyperglycemia and hyperglucagonemia when added to insulin therapy.

    • Conclusions:

    • Abnormal glucagon levels and hyperglycemia are not fully corrected by conventional diabetes treatments.
    • Suppressing excess glucagon secretion may offer a future therapeutic strategy for managing diabetes in humans.